Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691197 · ClinicalTrials.gov registry record · Phase 2
Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear
A Phase 2 study of Ametropia, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
- 1
- Study location
NCT00691197: Completed Phase 2 study of Ametropia, sponsored by Allergan.
NCT00691197 is a Phase 2 study of Ametropia that has completed, run by Allergan. The registered enrollment target is 246 participants, above the 106-participant average among 5 other Ametropia trials with a reported enrollment target (132% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00691197, a Phase 2 study of Ametropia, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
- 1
- Study location
Study Summary
Testing the Safety and Acceptability of Using a Rewetting Drop with Contact Lenses
Primary Outcome
Percentage of Subjects Tabulated by Changes in Line Number at Day 90 from Baseline; Visual Acuity measured by LogMar reported as Snellen equivalents. Better: an increase of 2 lines or more in at least one eye; No Change: a change less than +/- 2 lines in both eyes; Worse: a decrease of 2 lines or more in at least one eye.
Conditions Studied
Interventions
- DEVICE Carboxymethylcellulose sodium and Glycerin
- DEVICE Carboxymethylcellulose sodium
Study Locations (1)
California
- - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00691197 record still lists
NCT00691197 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, above the 106-participant average among 5 other Ametropia trials with a reported enrollment target (132% higher).
The record links to 1 condition, with Ametropia appearing as the primary indexed condition, and to 2 interventions - of which Carboxymethylcellulose sodium and Glycerin is the first listed.
NCT00691197 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00691197 about?
NCT00691197 is a clinical study titled "Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear". Testing the Safety and Acceptability of Using a Rewetting Drop with Contact Lenses
What is the current status of trial NCT00691197?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2008-03. Estimated completion is 2008-10.
What conditions does trial NCT00691197 study?
This clinical trial studies the following conditions: Ametropia.
What interventions are being tested in trial NCT00691197?
The interventions under investigation include: Carboxymethylcellulose sodium and Glycerin (DEVICE), Carboxymethylcellulose sodium (DEVICE).
Who is sponsoring clinical trial NCT00691197?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00691197 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ametropia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
North American Comfilcon A Clinical Study
RECRUITING
-
Post Marketing Clinical Study on the Efficacy of Lenses From a New Prescription Protocol
RECRUITING · NA
-
Clinical Performance of Two Commercial, Daily Disposable Contact Lenses
COMPLETED · NA
-
Apioc Contact Lens Feasibility
COMPLETED · NA
-
Evaluation of Monthly Replacement Lenses in Habitual Soft Contact Lens Wearers Who Report Frequent Digital Devise Use
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia